Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
748.71
-1.08 (-0.14%)
At close: Dec 18, 2025, 4:00 PM EST
747.79
-0.92 (-0.12%)
After-hours: Dec 18, 2025, 7:53 PM EST
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 15,106 employees as of December 31, 2024. The number of employees increased by 1,656 or 12.31% compared to the previous year.
Employees
15,106
Change (1Y)
1,656
Growth (1Y)
12.31%
Revenue / Employee
$943,188
Profits / Employee
$303,058
Market Cap
76.82B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15,106 | 1,656 | 12.31% |
| Dec 31, 2023 | 13,450 | 1,599 | 13.49% |
| Dec 31, 2022 | 11,851 | 1,483 | 14.30% |
| Dec 31, 2021 | 10,368 | 1,245 | 13.65% |
| Dec 31, 2020 | 9,123 | 1,023 | 12.63% |
| Dec 31, 2019 | 8,100 | 700 | 9.46% |
| Dec 31, 2018 | 7,400 | 1,200 | 19.35% |
| Dec 31, 2017 | 6,200 | 800 | 14.81% |
| Dec 31, 2016 | 5,400 | 1,100 | 25.58% |
| Dec 31, 2015 | 4,300 | 1,375 | 47.01% |
| Dec 31, 2014 | 2,925 | 585 | 25.00% |
| Dec 31, 2013 | 2,340 | 390 | 20.00% |
| Dec 31, 2012 | 1,950 | 246 | 14.44% |
| Dec 31, 2011 | 1,704 | 309 | 22.15% |
| Dec 31, 2010 | 1,395 | 366 | 35.57% |
| Dec 31, 2009 | 1,029 | 110 | 11.97% |
| Dec 31, 2008 | 919 | 237 | 34.75% |
| Dec 31, 2007 | 682 | 109 | 19.02% |
| Dec 31, 2006 | 573 | -15 | -2.55% |
| Dec 31, 2005 | 588 | -142 | -19.45% |
| Dec 31, 2004 | 730 | 86 | 13.35% |
| Dec 31, 2003 | 644 | -25 | -3.74% |
| Dec 31, 2002 | 669 | 94 | 16.35% |
| Dec 31, 2001 | 575 | 84 | 17.11% |
| Dec 31, 2000 | 491 | 54 | 12.36% |
| Dec 31, 1999 | 437 | 66 | 17.79% |
| Dec 31, 1998 | 371 | 101 | 37.41% |
| Dec 31, 1997 | 270 | 27 | 11.11% |
| Dec 31, 1996 | 243 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
REGN News
- 8 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript - Seeking Alpha
- 8 days ago - Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial - Reuters
- 10 days ago - Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention? - Seeking Alpha
- 11 days ago - Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment - GlobeNewsWire
- 12 days ago - Regeneron's experimental therapy combo effective in untreated cancer patients - Reuters
- 15 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 16 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha
- 17 days ago - Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire